开发下一代3D打印用于宫颈癌混合近距离放疗:一种引导式插植技术,可提高灵活性、剂量学与效率
本研究开发了3D打印的TARGIT-FX模板,并与原版TARGIT模板在宫颈癌近距离放疗中比较剂量学与操作流程。单机构回顾性队列研究纳入41例患者共148次植入,TARGIT-FX组平均V100%更高(+2.8%,P=.0019),患者层面D90更高(+2.0 Gy,P=.037)、D98更高(+2.7 Gy,P=.016),危及器官剂量总体相似,操作时间平均缩短30%(P<.0001)。
要点
- TARGIT-FX组较原版TARGIT组平均V100%提高2.8%(P=.0019)。
- 患者层面TARGIT-FX组D90提高2.0 Gy(P=.037)、D98提高2.7 Gy(P=.016)。
- TARGIT-FX组操作时间平均缩短30%(P<.0001)。
核心结论
- 与先前使用的TARGIT相比,TARGIT-FX实现了更短的操作时间、更高的肿瘤覆盖和相似的正常组织保护,展示了3D打印在提高宫颈癌近距离放疗宫腔内/插植操作技术效率和缩短学习曲线方面的潜力。
研究设计与样本
- 单机构回顾性队列研究,纳入接受TARGIT与TARGIT-FX模板辅助的宫腔加卵圆体(T&O)近距离放疗作为宫颈癌根治性治疗一部分的患者,共41例患者、148次植入。
- 原版TARGIT使用时间为2019年11月至2022年2月,TARGIT-FX使用时间为2022年3月至2022年11月。
主要发现
- 148次植入中,68次(46%)使用TARGIT,80次(54%)使用TARGIT-FX。
- 植入层面,TARGIT-FX组较原版TARGIT组平均V100%提高2.8%(P=.0019)。
- 患者层面,TARGIT-FX组较原版TARGIT组D90提高2.0 Gy(P=.037)、D98提高2.7 Gy(P=.016)。
- 两组模板危及器官剂量总体相似。
- TARGIT-FX组操作时间较原版TARGIT组平均缩短30%(P<.0001);高危临床靶区体积≥30 cc的植入亚组平均缩短28%(P=.013)。
关键数值与推荐
- TARGIT-FX设计特点为完全延伸至阴道口,具有9个针道,并允许在操作过程中及计算机断层扫描/磁共振成像后增加针或调整深度。
- 所有接受调查的住院医师(100%,N=6)表示TARGIT-FX针插入易于使用,并有兴趣在未来实践中应用该技术。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We developed a 3-dimensionally (3D) printed tandem anchored radially guiding interstitial template (TARGIT) to increase the simplicity of intracavitary/interstitial technique for tandem-and-ovoid (T&O) procedures in cervical cancer brachytherapy. This study compared dosimetry and procedure logistics between T&O implants using the original TARGIT versus the next-generation TARGIT-Flexible-eXtended (TARGIT-FX) 3D-printed template designed for practice-changing ease-of-use with further simplified needle insertion and increased flexibility in needle placement. METHODS AND MATERIALS: This single-institution retrospective cohort study included patients undergoing T&O brachytherapy as part of definitive cervical cancer treatment. Procedures used the original TARGIT from November 2019 through February 2022 and the TARGIT-FX from March 2022 through November 2022. The FX design features full extension to the vaginal introitus with 9 needle channels and allows for needle additions or depth adjustments intraprocedure and after computed tomography/magnetic resonance imaging. RESULTS: A total of 148 implants were performed, 68 (46%) with TARGIT and 80 (54%) with TARGIT-FX, across 41 patients. Across implants, the TARGIT-FX achieved higher mean V100% (+2.8%, P = .0019), and across patients, the TARGIT-FX achieved higher D90 (+2.0 Gy, P = .037) and higher D98 (+2.7 Gy, P = .016) compared with the original TARGIT. Doses to organs at risk were overall similar between templates. Procedure times for TARGIT-FX implants were 30% shorter on average than for those using the original TARGIT (P < .0001), and 28% shorter on average for the subset of implants with high-risk clinical target volume ≥30 cc (P = .013). All residents (100%, N = 6) surveyed regarding the TARGIT-FX indicated ease-of-use for needle insertion and interest in applying the technique in future practice. CONCLUSIONS: The TARGIT-FX achieved shorter procedure times with increased tumor coverage and similar normal tissue sparing compared with the previously applied TARGIT and illustrates the potential of 3D printing to enhance efficiency and shorten the learning curve for intracavitary/interstitial procedure technique in cervical cancer brachytherapy.
引用
- Marar M, Niedermayr T, Kidd EA, et al. Developing Next-Generation 3-Dimensional Printing for Cervical Cancer Hybrid Brachytherapy: A Guided Interstitial Technique Enabling Improved Flexibility, Dosimetry, and Efficiency. Int J Radiat Oncol Biol Phys. 2023. PMID: 37059235. doi:10.1016/j.ijrobp.2023.04.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。